0001179110-14-011698.txt : 20140711 0001179110-14-011698.hdr.sgml : 20140711 20140711173226 ACCESSION NUMBER: 0001179110-14-011698 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140709 FILED AS OF DATE: 20140711 DATE AS OF CHANGE: 20140711 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SYDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SYDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sherman Matthew L CENTRAL INDEX KEY: 0001325710 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 14972447 MAIL ADDRESS: STREET 1: C/O ACCELERON PHARMA INC STREET 2: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2014-07-09 0 0001280600 ACCELERON PHARMA INC XLRN 0001325710 Sherman Matthew L 128 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 SVP & Chief Medical Officer Common Stock 2014-07-09 4 M 0 6000 0.48 A 19858 D Common Stock 2014-07-09 4 S 0 2906 28.55 D 16952 D Common Stock 2014-07-09 4 S 0 3094 29.39 D 13858 D Common Stock 2014-07-09 4 S 0 1001 28.77 D 31499 I By GRAT Common Stock 2014-07-09 4 S 0 499 29.46 D 31000 I By GRAT Option to Purchase Common Stock 0.48 2014-07-09 4 M 0 6000 0 D 2016-05-31 Common Stock 47765 41765 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2014. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.16 to $29.15, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.17 to $29.66, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.28 to $29.18, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.33 to $29.58, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. The options of registrant's common stock vested as to 25% of the shares on the first anniversary of the grant and in equal installments quarterly thereafter. /s/ John Quisel, as attorney-in-fact for Matthew L. Sherman 2014-07-11